Granulocyte stimulating factor in patients on peritoneal dialysis and LPS stimulated peripheral blood mononuclear cells.
Dialysate and serum levels of granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF) and leukemia inhibitory factor (LIF) were analyzed in patients with continuous ambulatory peritoneal dialysis (CAPD). Samples from the peritoneal effluent and from serum were obtained during the first months of dialysis and during peritonitis from the first three dialysate bags drained on the day of admittance and form nightbags on days three and ten. Serum samples were drawn on days one and ten. On the first day of infection G-CSF was detected in twelve out of fifteen samples in the dialysate and reached its peak median level, 443 pg/ml, in the first drained bag and thereafter decreased significantly. Also in serum a peak, 190 pg/ml, was observed on the first day. LIF was found in six of ten analyzed dialysate samples, with a peak median level of 77 pg/ml on day one, while only four of ten patients had detectable GM-CSF. Peripheral blood mononuclear cells from non-infected CAPD patients were stimulated with lipopolysaccharide and G-CSF levels in the supernatants increased significantly (P < 0.05) after 6 h stimulation. We conclude that G-CSF is produced locally in the dialysate during the acute stage of peritonitis and to a lesser extent also systemically. These findings are in line with G-CSF production after LPS stimulation of peripheral blood mononuclear cells.
Department of Microbiology, Karolinska Hospital, Stockholm, Sweden.
A
A
Brauner
B
B
Hylander
Y
Y
Lu
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001202:Ascitic Fluid / Q000378:metabolism / Q000382:microbiology; D001424:Bacterial Infections / Q000097:blood / Q000209:etiology / Q000378:metabolism; D015314:Dialysis Solutions; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000097:blood / Q000378:metabolism*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000097:blood / Q000378:metabolism; D006131:Growth Inhibitors / Q000097:blood / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000494:pharmacology; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008222:Lymphokines / Q000097:blood / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D010538:Peritonitis / Q000097:blood / Q000209:etiology / Q000378:metabolism; D013997:Time Factors
D015314:Dialysis Solutions; D006131:Growth Inhibitors; D007375:Interleukin-1; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008070:Lipopolysaccharides; D008222:Lymphokines; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor